GBGHOLDINGS：FIRSTQUARTERLYRESULTSANNOUNCEMENTFORTHETHREEMONTHSENDED30JUNE2022.pdf

《GBGHOLDINGS：FIRSTQUARTERLYRESULTSANNOUNCEMENTFORTHETHREEMONTHSENDED30JUNE2022.pdf》由會員分享，可在線閱讀，更多相關《GBGHOLDINGS：FIRSTQUARTERLYRESULTSANNOUNCEMENTFORTHETHREEMONTHSENDED30JUNE2022.pdf（18頁珍藏版）》請在三個皮匠報告上搜索。

1、 1 Hong Kong Exchanges and Clearing Limited and the Hong Kong Stock Exchange take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon

2、the whole or any part of the contents of this announcement.GRAND BRILLIANCE GROUP HOLDINGS LIMITED君 百 延 集 團 控 股 有 限 公 司(Incorporated in the Cayman Islands with limited liability)(Stock Code:8372)FIRST QUARTERLY RESULTS ANNOUNCEMENTFOR THE THREE MONTHS ENDED 30 JUNE 2022CHARACTERISTICS OF GEM OF THE

3、STOCK EXCHANGE OF HONG KONG LIMITED(THE“HONG KONG STOCK EXCHANGE”)GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Hong Kong Stock Exchange.Prospective investors should be aw

4、are of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.Given the emergin

5、g nature of companies listed on GEM,there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Hong Kong Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.Th

6、is announcement,for which the directors(the“Directors”)of Grand Brilliance Group Holdings Limited(the“Company”,together with its subsidiaries,the“Group”or“We”)collectively and individually accept full responsibility,includes particulars given in compliance with the Rules Governing the Listing of Sec

7、urities on GEM of the Hong Kong Stock Exchange(the“GEM Listing Rules”)for the purpose of giving information with regard to the Group.The Directors,having made all reasonable enquiries,confirm that,to the best of their knowledge and belief:(1)the information contained in this announcement is accurate

8、 and complete in all material respects and not misleading and deceptive;(2)there are no other matters the omission of which would make any statement in this announcement misleading;and(3)all opinions expressed in this announcement have been arrived at after due and careful consideration and are foun

9、ded on bases and assumptions that are fair and reasonable.2 FIRST QUARTERLY RESULTSThe board of the Directors(the“Board”)of the Company is pleased to announce the unaudited condensed consolidated results of the Group for the three months ended 30 June 2022,together with the comparative figures for t

10、he corresponding period in 2021,as follows:CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOMEFor the three months ended 30 June 2022For the three monthsended 30 June20222021NotesHK$000HK$000(Unaudited)(Unaudited)Revenue415,69614,006Cost of revenue(7,818)(6,731)Gross profit7,8787,275Other incom

11、e28012Other gains or losses1852Distribution and selling expenses(328)(249)Administrative and other operating expenses(6,495)(6,179)Finance costs5(34)(34)Share of losses of an associate(20)Profit before income tax61,299877Income tax expense7(220)(150)Profit and total comprehensive income for the peri

12、od attributable to owners of the Company1,079727 HK centHK centEarnings per share attributable to owners of the CompanyBasic and diluted earnings per share90.130.09 3 CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITYFor the three months ended 30 June 2022Share capitalShare premiumMerger reserveS

13、hare option reserveRetained earningsTotalHK$000HK$000HK$000HK$000HK$000HK$000At 1 April 2021(audited)8,00052,4991,5001,00630,04793,052Profit and total comprehensive income for the period727727Recognition of equity-settled share-based payment99Dividend declared(note 8)(3,600)(3,600)At 30 June 2021(un

14、audited)8,00052,4991,5001,01527,17490,188 At 1 April 2022(audited)8,00052,4991,5001,01530,49593,509Profit and total comprehensive income for the period1,0791,079Dividend declared(note 8)(2,400)(2,400)At 30 June 2022(unaudited)8,00052,4991,5001,01529,17492,188 4 NOTES TO THE CONDENSED CONSOLIDATED FI

15、NANCIAL STATEMENTSFor the three months ended 30 June 20221.GENERAL INFORMATIONThe Company was incorporated in the Cayman Islands with limited liability under the Companies Law,Cap.22 of the Cayman Islands on 5 July 2017.Its shares have been listed on GEM of the Hong Kong Stock Exchange on 29 March 2

16、018(the“Listing”).The address of the Companys registered office is situated at Cricket Square,Hutchins Drive,P.O.Box 2681,Grand Cayman,KY1-1111,Cayman Islands.The principal place of business of the Company is situated at Units 290103 and 2905,29/F,The Octagon,6 Sha Tsui Road,Tsuen Wan,New Territorie

17、s,Hong Kong.The Company is an investment holding company and its subsidiaries are principally engaged in supplying medical devices and providing medical device solutions including market trend analysis,sourcing of medical devices,after-sale services,technical support and training services,medical de

18、vices leasing services and quality assurance.The Companys parent company is B&A Success Limited(“B&A Success”),a company incorporated in the British Virgin Islands.In the opinion of the Directors,B&A Success is also the ultimate parent of the Company.The condensed consolidated financial statements a

19、re presented in Hong Kong dollars(“HK$”),which is the same as the functional currency of the Group.2.BASIS OF PREPARATIONThe condensed consolidated financial statements have been prepared in accordance with all applicable Hong Kong Financial Reporting Standards,Hong Kong Accounting Standards and Int

20、erpretations(hereinafter collectively referred to as the“HKFRSs”)issued by the Hong Kong Institute of Certified Public Accountants,the disclosure requirements of the Hong Kong Companies Ordinance and the GEM Listing Rules.The condensed consolidated financial statements do not include all the informa

21、tion and disclosures required in the annual financial statements,and should be read in conjunction with the Groups annual financial statements for the year ended 31 March 2022.The condensed consolidated financial statements have been prepared under the historical cost basis,except for certain financ

22、ial instruments which are measured at fair values.The accounting policies adopted in preparing the unaudited condensed consolidated results for the three months ended 30 June 2022 are consistent with those adopted in the audited financial statements for the year ended 31 March 2022,except for a numb

23、er of amendments to HKFRSs issued by the Hong Kong Institute of Certified Public Accountants that are effective for the current accounting period of the Group.The adoption of these new and revised HKFRSs has had no material effect on the Groups results and financial position for the current or prior

24、 periods have been prepared or presented.5 The Group has not early adopted any new and revised HKFRSs that have been issued but are not yet effective.The condensed consolidated financial statements for the three months ended 30 June 2022 have not been audited by the Companys auditors,but have been r

25、eviewed by the audit committee of the Company(the“Audit Committee”).3.SEGMENT INFORMATION(a)Operating segment informationThe Group determines its operating segments based on the reports reviewed by the chief operating decision-maker,i.e.Directors of the Company who are used to make strategic decisio

26、ns.During the reporting periods,the Directors assess the operating performance and allocate the resources of the Group as a whole as the Group is primarily engaged in supplying medical devices and providing medical device solutions including market trend analysis,sourcing of medical devices,after-sa

27、le services,technical support and training services,medical devices leasing services and quality assurance.Therefore the Group has only one operating segment that qualifies as reportable segment under HKFRS 8 Operating Segment.(b)Geographical segment informationThe Company is an investment holding c

28、ompany and the principal place of the Groups operations is in Hong Kong.Accordingly,management determines that the Group is domiciled in Hong Kong.All of the Groups revenue are derived from and most of the Groups non-current assets are located in Hong Kong.Accordingly,no separate segmental analysis

29、is presented.(c)Disaggregation of revenue from contracts with customersFor the three months ended30 June20222021HK$000HK$000(Unaudited)(Unaudited)Timing of revenue recognitionOver time493405At a point in time15,16413,542 15,65713,947 (d)Information about major customersFor the three months ended 30

30、June 2022 and 2021,no revenue from a single customer accounted for 10%or above of the total revenue of the Group.6 4.REVENUEThe Group is principally engaged in supplying medical devices and providing medical device solutions including market trend analysis,sourcing of medical devices,after-sale serv

31、ices,technical support and training services,medical devices leasing services and quality assurance.Revenue derived from the principal activities comprises the following:For the three months ended30 June20222021HK$000HK$000(Unaudited)(Unaudited)Revenue from contracts with customers:Sales of medical

32、devices and products Medical consumables11,97010,351 Medical equipment2,8882,919 Medical instruments30627215,16413,542Rendering of maintenance services493405 15,65713,947Revenue from other source:Rental income from leasing medical devices3959 15,69614,006 5.FINANCE COSTSFor the three months ended30

33、June20222021HK$000HK$000(Unaudited)(Unaudited)Interest expenses on lease liabilities3434 7 6.PROFIT BEFORE INCOME TAXProfit before income tax is arrived at after charging/(crediting):For the three months ended30 June20222021HK$000HK$000(Unaudited)(Unaudited)Cost of inventories recognised as expense#

34、Carrying amount of inventories consumed7,1976,181(Reversal of)/allowance for inventories(89)124 7,1086,305 Change in fair value of financial asset measured at fair value through profit or loss(61)3Depreciation of property,plant and equipment*111180Depreciation of right-of-use assets984877Employee co

35、sts(including directors emoluments)Salaries,allowances and other benefits3,9833,691 Equity-settled share-based payment expenses9 Contributions to defined contribution retirement plan135130 4,1183,830 Bank interest income(10)Exchange difference,net130(63)Research and development expenditure619145(Rev

36、ersal)/provision of loss allowance for trade receivables(87)8#Included in cost of revenue*Included in administrative and other operating expenses Included in research and development expenditure are staff costs amounted to approximately HK$614,000 for the three months ended 30 June 2022(three months

37、 ended 30 June 2021:HK$141,000)which have been included in the employee costs above.For the three months ended 30 June 2022,no forfeited contribution in respect of the defined contribution retirement plans were utilised by the Group to reduce the contribution payable to the plans(three months ended

38、30 June 2021:nil).As at 30 June 2022,no forfeited contribution under these plans is available to reduce future contribution(three months ended 30 June 2021:nil).8 7.INCOME TAX EXPENSEThe amount of income tax expense in the condensed consolidated statement of comprehensive income represents:For the t

39、hree months ended30 June20222021HK$000HK$000(Unaudited)(Unaudited)Current tax for the period Hong Kong Profits Tax21688Deferred tax462 220150 The Group has no income subject to taxation in the Cayman Islands,the British Virgin Islands and United Kingdom.The Company and its Hong Kong incorporated sub

40、sidiaries are subject to Hong Kong Profits Tax,which is calculated at tax rate of 16.5%on the estimated assessable profits arising in Hong Kong during the year,except for one subsidiary of the Company which is a qualifying entity under the two-tiered profits tax rates regime.The first HK$2,000,000 o

41、f assessable profits of this subsidiary are taxed at 8.25%and the remaining assessable profits are taxed at 16.5%.8.DIVIDENDSThe Board does not recommend or declare the payment of a dividend for the three months ended 30 June 2022(three months ended 30 June 2021:Nil).For the three months ended30 Jun

42、e20222021HK$000HK$000(Unaudited)(Unaudited)Interim dividend for the year ended 31 March 2022 of HK0.3 cent per share(2021:HK0.45 cent per share)2,4003,600 Note:An interim dividend of HK0.3 cent per ordinary share for the year ended 31 March 2022 was declared by the Board,which will be paid on or bef

43、ore Monday,15 August 2022 to the shareholders of the Company whose names appear on the register of members on Friday,8 July 2022.9 9.EARNINGS PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANYThe calculation of basic and diluted earnings per share is based on the following data:For the three months end

44、ed30 June20222021HK$000HK$000(Unaudited)(Unaudited)EarningsProfit for the period attributable to owners of the Company1,079727 000000Weighted average number of ordinary shares in issueWeighted average number of ordinary shares for the purpose of calculating basic and diluted earnings per share800,00

45、0800,000 For the purpose of calculating diluted earnings per share for the three months ended 30 June 2022 and 2021,no adjustment has been made as the exercise of the outstanding share options has an anti-dilutive effect of the basic earnings per share.10 MANAGEMENT DISCUSSION AND ANALYSISBUSINESS R

46、EVIEWWe are an established medical device distributor and one-stop medical device solutions provider with over 20 years of experience in the medical device market in Hong Kong.For the three months ended 30 June 2022,the Group continued to implement our business strategy to solidify our position as a

47、 major medical device distributor in Hong Kong.We have established an associate company which will facilitate and bring about the Groups future business development in developing and establishing autonomous mobile robot solutions in the healthcare industries in order to support and sustain the growt

48、h of our business and expand our business.The Group achieved its business growth through diversifying the product portfolio and enhance our research and development ability.During the period under review,the COVID-19 pandemic continues to affect the Hong Kongs economy.The Group will further expand t

49、he product portfolio and enhance the customer services to enhance our one-stop medical device solutions services.We continue to be optimistic on the outlook of the medical and healthcare industry,attributable to the increase of aging population and rising healthcare awareness of the public in Hong K

50、ong together with our automation solution to eliminate the medical manpower shortage crisis in Hong Kong.The Group is looking for suitable investment opportunities to diversify business and bring better investment return to the shareholders of the Company.11 FINANCIAL REVIEWRevenueThe Groups revenue

51、 increased by approximately 12%,from approximately HK$14.0 million for the three months ended 30 June 2021 to approximately HK$15.7 million for the three months ended 30 June 2022.The increase was primarily attributable to the increase in revenue generated from medical consumables.Gross profit and g

52、ross profit marginThe Group recorded gross profit of approximately HK$7.9 million for the three months ended 30 June 2022,representing an increase by approximately HK$0.6 million or 8%,as compared to approximately HK$7.3 million for the three months ended 30 June 2021.Gross profit margin decreased f

53、rom approximately 51.9%for the three months ended 30 June 2021 to approximately 50.2%for the three months ended 30 June 2022.Administrative and other operating expensesAdministrative and other operating expenses mainly included auditors remuneration,advertising and marketing expenses,depreciation,Di

54、rectors remuneration,legal and professional fee,rent,rates and management fee for office and warehouses,staff costs,travelling and entertainment expenses and other miscellaneous expenses.Administrative and other operating expenses for the three months ended 30 June 2022 amounted to approximately HK$

55、6.5 million,representing an increase by approximately HK$0.3 million or 5.1%,as compared to approximately HK$6.2 million for the three months ended 30 June 2021.The increase was primarily attributable to the increase in the staff cost,including Directors remuneration.The increase in staff cost was m

56、ainly attributable to increase of workforce of the Group for the three months ended 30 June 2022.12 Income tax expensesIncome tax expenses for the three months ended 30 June 2022 amounted to approximately HK$0.2 million(three months ended 30 June 2021:approximately HK$0.2 million).Profit for the per

57、iodThe Groups profit increased by approximately HK$0.4 million from approximately HK$0.7 million for the three months ended 30 June 2021 to approximately HK$1.1 million for the three months ended 30 June 2022.The increase was primarily attributable to(i)increase in gross profit and(ii)an one-off emp

58、loyment support scheme government grant for the three months ended 30 June 2022.DividendThe Board has resolved not to declare dividend for the three months ended 30 June 2022(three months ended 30 June 2021:Nil).DIRECTORS AND CHIEF EXECUTIVES INTEREST AND SHORT POSITIONS IN SHARES,UNDERLYING SHARES

59、OR DEBENTURES OF THE COMPANY OR ANY ASSOCIATED CORPORATIONAs at 30 June 2022,the interests and short positions of the Directors and chief executive of the Company in the shares,underlying shares or debentures of the Company or any of its associated corporations(within the meaning of Part XV of the S

60、ecurities and Futures Ordinance(the“SFO”)which shall have to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO(including interests and short positions which they are taken or deemed to have under such provisions of the SFO)or which shall

61、be required,pursuant to section 352 of the SFO,to be recorded in the register referred to therein or which shall be required to notify the Company and the Hong Kong Stock Exchange pursuant to Rule 5.46 to Rule 5.67 of the GEM Listing Rules,were as follows:13 Long position in shares of the Company an

62、d associated corporationsName of Director/chief executiveName of Groupmember/associatedcorporationNature of InterestNumber ofsharesNumber ofunderlyingsharesAggregateInterestApproximatepercentage ofshareholdingMs.Wong Bik Kwan Bikie(“Ms.Wong”)(Note 1)The CompanyInterest in a controlled corporation557

63、,424,000Beneficial owner7,980,000 557,424,0007,980,000565,404,00070.68%B&A Success Beneficial owner100 shares ofUS$1.00 each100%Dr.Miu Yin Shun Andrew(“Dr.Miu”)(Note 2)The CompanyInterest of spouse557,424,0007,980,000565,404,00070.68%Mr.Chiu Man Wai(“Mr.Chiu”)(Note 3)The CompanyInterest in a control

64、led corporation20,224,00120,224,0012.53%Infinite Crystal LimitedBeneficial owner900 shares ofUS$1.00 each100%Mr.Chow Ming Po AaronThe CompanyBeneficial owner7,810,0007,810,0000.98%Notes:1.The shares are registered in the name of B&A Success,the entire issued share capital of which is legally and ben

65、eficially owned by Ms.Wong.Under the SFO,Ms.Wong is deemed to be interested in the same number of shares held by B&A Success.2.Dr.Miu is the spouse of Ms.Wong.Under the SFO,Dr.Miu is deemed to be interested in the same number of shares deemed to be held by Ms.Wong.3.The shares are registered in the

66、name of Infinite Crystal Limited,the entire issued share capital of which is legally and beneficially owned by Mr.Chiu.Under the SFO,Mr.Chiu is deemed to be interested in the same number of shares held by Infinite Crystal Limited.14 Save as disclosed above,as at 30 June 2022,none of the Directors an

67、d chief executive of the Company had any interests or short positions in any shares,underlying shares and debenture of the Company or any of its associated corporations(within the meaning of Part XV of the SFO)which would have to be notified to the Company and the Hong Kong Stock Exchange pursuant t

68、o Divisions 7 and 8 of Part XV of the SFO(including interests or short positions which they were taken or deemed to have under such provisions of the SFO),or which were recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO,or which were required to be notifie

69、d to the Company and the Hong Kong Stock Exchange,pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules.SUBSTANTIAL SHAREHOLDERS AND OTHER PERSONS INTERESTS AND SHORT POSITIONS IN SHARES OR UNDERLYING SHARES OF THE COMPANYAs at 30 June 2022,so far as the Directors are aware,other than the Director

70、s or chief executive of the Company whose interests are disclosed under the paragraph headed“Directors and chief executives interest and short positions in shares,underlying shares or debentures of the Company or any associated corporation”above,the following persons had an interest or short positio

71、n in the shares or underlying shares of the Company which shall be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO,or,directly or indirectly,were interested in 5.0%or more of the issued voting shares of any member of the Group:Long position in the shares of t

72、he CompanyName of shareholdersNature of InterestTotal number of sharesApproximate percentage of shareholdingB&A SuccessBeneficial owner557,424,00069.68%Saved as disclosed above and so far as is known to the Directors,the Directors were not aware of any other persons other than the Directors or chief

73、 executive of the Company who held an interest or short positions in the shares and underlying shares of the Company as at 30 June 2022 which required to be recorded pursuant to section 336 of the SFO.15 SHARE OPTION SCHEMEThe Company has adopted a share option scheme(“Share Option Scheme”)on 1 Marc

74、h 2018 to enable the Company to grant options to selected participants as incentives or rewards for their contribution to the Group and continuing efforts to promote the interest of the Group.The terms of the Share Option Scheme are in accordance with Chapter 23 of the GEM Listing Rules.Details of S

75、hare Options and their movements during the three months ended 30 June 2022 are as follows:Number of Shares issuable under the optionsDate of GrantExerciseprice perShareas at01/04/2022grantedduring theperiodexercisedduring theperiodlapsedduring theperiodas at30/06/2022ExerciseperiodHK$DirectorMs.Won

76、g18/04/20190.127,980,0007,980,000Note 1Employees of the GroupIn aggregate18/04/20190.1213,480,00013,480,000Note 1 21,460,00021,460,000 Notes:1.(i)up to 40%of the Share Options are exercisable on or after 18 April 2019;(ii)up to 70%of the Share Options are exercisable on or after 18 April 2020;(iii)a

77、ll the remaining Share Options are exercisable on or after 18 April 2021;and in each case,not later than 17 April 2024.2.The closing price of the shares as stated in the Stock Exchanges daily quotations sheet immediately before the date on which the share options are granted(i.e.17 April 2019)was HK

78、$0.12.Save as disclosed above,no options were granted,exercised,forfeited,cancelled or lapsed during the three months ended 30 June 2022.16 PURCHASE,SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANYNeither the Company nor any of its subsidiaries had purchased,sold or redeemed any of the Company

79、s listed securities during the three months ended 30 June 2022.DIRECTORS SECURITIES TRADING TRANSACTIONSThe Group has adopted a code of conduct set out in the“required standard of dealings”in Rules 5.48 to 5.67 of the GEM Listing Rules.Having made specific enquiry of all Directors,all Directors have

80、 confirmed that they have been complying with the required standard of dealings and the related code of conduct regarding directors securities transactions during the three months ended 30 June 2022.As far as the Group is aware,the Directors and employees of the Group have not breached the required

81、standard of dealings and the code of conduct.DIRECTORS INTEREST IN COMPETING BUSINESSNone of the Directors and Directors of the Companys subsidiaries,or any of their respective associates,as defined in the GEM Listing Rules,had interest in any business that competes or may compete,either directly or

82、 indirectly,with the businesses of the Group or has any other conflict of interests with the Group(other than being a director of the Company and/or its subsidiaries and their respective associates)during the three months ended 30 June 2022.17 CORPORATE GOVERNANCE PRACTICEThe Corporate Governance Co

83、de was amended on 1 January 2022(the“New Code”),with majority of the amendments applying to financial year beginning on or after 1 January 2022.As this announcement relates to financial year of the Company commencing on 1 April 2022,the numbering of code provisions in this announcement follows the c

84、ode provisions of the New Code.The Group has adopted the code provisions of the New Code as set out in Appendix 15 to the GEM Listing Rules.During the three months ended 30 June 2022,the Group has complied with all the code provisions of the New Code,except for the deviation stipulated below.CHAIRMA

85、N AND CHIEF EXECUTIVE OFFICERAccording to the code provision C.2.1 of the CG Code,the roles of the chairman and chief executive should be separate and should not be performed by the same individual.For the three months ended 30 June 2022,the roles of chairman of the Board were performed by the chief

86、 executive officer,Ms.Wong.As the chairman of the Board,Ms.Wong is responsible for the formulating,planning and directing the Groups overall strategy and always seek for Board approval for any significant decisions and transactions.Although Ms.Wong performs both roles,the Board has conducted an asse

87、ssment and believed that the independence,effectiveness and functionality of the Board and the Groups operations has been and will be highly maintained together with independent check and balance measures in place as the Board has sufficient number of Directors who have diversified background and ex

88、pertise.18 AUDIT COMMITTEEThe Company established the Audit Committee on 1 March 2018 with written terms of reference in compliance with the GEM Listing Rules which are available on the website of the Hong Kong Stock Exchange and on the Companys website.The Audit Committee currently consists of two

89、independent non-executive Directors,namely Mr.Wong Lung Wo James and Mr.Chow Ming Po Aaron,and one non-executive Director,namely Dr.Miu Yin Shun Andrew.Mr.Wong Lung Wo James has the appropriate accounting and financial related management expertise and serves as the chairman of the Audit Committee.Th

90、e Audit Committee of the Company has reviewed the unaudited condensed consolidated financial statements of the Group for the three months ended 30 June 2022,and is of the opinion that such statements complied with the applicable accounting standards,the requirements under the GEM Listing Rules,and t

91、hat adequate disclosures have been made.By order of the BoardGrand Brilliance Group Holdings LimitedWong Bik Kwan BikieChairman and Chief Executive OfficerHong Kong,5 August 2022As at the date of this announcement,the executive Director is Ms.Wong Bik Kwan Bikie;the non-executive Directors are Dr.Mi

92、u Yin Shun Andrew and Mr.Chiu Man Wai;and the independent non-executive Directors are Mr.Ng Leung Sing SBS,JP,Mr.Wong Lung Wo James and Mr.Chow Ming Po Aaron.This announcement will remain on the“Latest Company Announcements”page of the GEM website()for at least seven days from the date of its publication and the website of the Company().